CL2014003443A1 - Compuestos derivados de n-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas; su metodo de produccion; compuestos intermediarios; producto medicinal que contiene al compuesto, util para el tratamiento y/o prevencion de enfermedades hiperproliferativas, las cuales son dependientes del receptor de androgenos. - Google Patents

Compuestos derivados de n-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas; su metodo de produccion; compuestos intermediarios; producto medicinal que contiene al compuesto, util para el tratamiento y/o prevencion de enfermedades hiperproliferativas, las cuales son dependientes del receptor de androgenos.

Info

Publication number
CL2014003443A1
CL2014003443A1 CL2014003443A CL2014003443A CL2014003443A1 CL 2014003443 A1 CL2014003443 A1 CL 2014003443A1 CL 2014003443 A CL2014003443 A CL 2014003443A CL 2014003443 A CL2014003443 A CL 2014003443A CL 2014003443 A1 CL2014003443 A1 CL 2014003443A1
Authority
CL
Chile
Prior art keywords
compounds
quinolin
yloxy
cyclohexyl
methyl
Prior art date
Application number
CL2014003443A
Other languages
English (en)
Inventor
Duy Nguyen
Hermann Fallecido Künzer
Gimenez Hortensia Faus
Benjamin Bader
Silke Köhr
Martin Fritsch
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003443(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2014003443A1 publication Critical patent/CL2014003443A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se relaciona con N-[4-(quinolin-4-iloxi)ciclohexil(metil)] (hete-ro)arilcarboxamidas, intermediarios y métodos para su producción, uso de las mismas para tratar y/o prevenir enfermedades y uso de las mismas para producir productos medicinales y uso de los mismos para tratar y/o prevenir enfermeda-des, en especial enfermedades hiperproliferativas.
CL2014003443A 2012-06-26 2014-12-18 Compuestos derivados de n-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas; su metodo de produccion; compuestos intermediarios; producto medicinal que contiene al compuesto, util para el tratamiento y/o prevencion de enfermedades hiperproliferativas, las cuales son dependientes del receptor de androgenos. CL2014003443A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12004764 2012-06-26

Publications (1)

Publication Number Publication Date
CL2014003443A1 true CL2014003443A1 (es) 2015-06-26

Family

ID=48699019

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003443A CL2014003443A1 (es) 2012-06-26 2014-12-18 Compuestos derivados de n-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas; su metodo de produccion; compuestos intermediarios; producto medicinal que contiene al compuesto, util para el tratamiento y/o prevencion de enfermedades hiperproliferativas, las cuales son dependientes del receptor de androgenos.

Country Status (41)

Country Link
US (1) US9428460B2 (es)
EP (1) EP2864291B1 (es)
JP (1) JP6181172B2 (es)
KR (1) KR20150023880A (es)
AP (1) AP3919A (es)
AR (1) AR091565A1 (es)
AU (1) AU2013283543B2 (es)
BR (1) BR112014032538A2 (es)
CA (1) CA2877786C (es)
CL (1) CL2014003443A1 (es)
CO (1) CO7170167A2 (es)
CR (1) CR20140593A (es)
CU (1) CU20140144A7 (es)
CY (1) CY1118412T1 (es)
DK (1) DK2864291T3 (es)
DO (1) DOP2014000295A (es)
EA (1) EA028063B1 (es)
EC (1) ECSP14032516A (es)
ES (1) ES2609455T3 (es)
HK (1) HK1206346A1 (es)
HR (1) HRP20161745T1 (es)
HU (1) HUE032306T2 (es)
IL (1) IL236146B (es)
JO (1) JO3342B1 (es)
LT (1) LT2864291T (es)
MA (1) MA37700B1 (es)
ME (1) ME02590B (es)
MX (1) MX2014016054A (es)
NZ (1) NZ703100A (es)
PE (1) PE20150154A1 (es)
PH (1) PH12014502869A1 (es)
PL (1) PL2864291T3 (es)
PT (1) PT2864291T (es)
RS (1) RS55500B1 (es)
SG (1) SG11201408254UA (es)
SI (1) SI2864291T1 (es)
TN (1) TN2014000532A1 (es)
TW (1) TWI600646B (es)
UA (1) UA115447C2 (es)
UY (1) UY34881A (es)
WO (1) WO2014001247A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2945819A1 (en) * 2014-04-22 2015-10-29 Nimbus Iris, Inc. Irak inhibitors and uses thereof
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3452451A4 (en) * 2016-05-04 2019-11-13 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
KR20190003686A (ko) 2016-05-04 2019-01-09 브리스톨-마이어스 스큅 컴퍼니 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328821A (en) 1991-12-12 1994-07-12 Robyn Fisher Cold and cryo-preservation methods for human tissue slices
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU2001268040A1 (en) 2000-06-23 2002-01-08 Eli Lilly And Company Methods and compounds for inhibiting mrp1
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
CN100528846C (zh) 2002-09-11 2009-08-19 株式会社吴羽 胺化合物及其用途
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
JP2006515014A (ja) 2003-01-30 2006-05-18 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド PKC−θのインヒビターとして有用な2,4−ジアミノピリミジン誘導体
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1725238A4 (en) 2004-03-17 2009-04-01 Glaxo Group Ltd ACETYLCHOLINE M 3 MUSCARINIC RECEPTOR ANTAGONISTS
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
WO2005117570A1 (en) 2004-05-27 2005-12-15 Jack Saffron Feeding dish to prevent pest infestation
RU2007119427A (ru) 2004-11-09 2008-12-20 СмитКлайн Бичем Корпорейшн (US) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
GB0509224D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
US20060293341A1 (en) 2005-06-23 2006-12-28 Vrej Jubian Alkyl sulfonamide derivatives
KR20080100238A (ko) 2006-02-06 2008-11-14 쇼와 덴코 가부시키가이샤 미백 피부 외용제
WO2007146824A2 (en) 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2008064432A1 (en) 2006-12-01 2008-06-05 The University Of Sydney Polycyclic molecular compounds
US8377949B2 (en) 2007-08-16 2013-02-19 Boehringer Ingelheim International Gmbh Quinazolinedione chymase inhibitors
CA2966280A1 (en) * 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
JP5699075B2 (ja) 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ
AU2009300328A1 (en) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
CN102471327A (zh) 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
CN102481294A (zh) 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses

Also Published As

Publication number Publication date
CU20140144A7 (es) 2015-08-27
AR091565A1 (es) 2015-02-11
PH12014502869B1 (en) 2015-02-23
CO7170167A2 (es) 2015-01-28
CA2877786A1 (en) 2014-01-03
SI2864291T1 (sl) 2017-01-31
LT2864291T (lt) 2017-01-10
UA115447C2 (uk) 2017-11-10
US20150191431A1 (en) 2015-07-09
BR112014032538A2 (pt) 2017-06-27
MX2014016054A (es) 2015-04-10
AP2014008141A0 (en) 2014-12-31
PL2864291T3 (pl) 2017-07-31
HK1206346A1 (en) 2016-01-08
US9428460B2 (en) 2016-08-30
CY1118412T1 (el) 2017-06-28
ECSP14032516A (es) 2015-12-31
PE20150154A1 (es) 2015-02-19
JP2015521641A (ja) 2015-07-30
AU2013283543B2 (en) 2017-11-02
AU2013283543A1 (en) 2015-01-29
NZ703100A (en) 2016-10-28
AP3919A (en) 2016-11-30
DK2864291T3 (en) 2017-01-16
RS55500B1 (sr) 2017-05-31
IL236146A0 (en) 2015-02-01
ME02590B (me) 2017-06-20
IL236146B (en) 2018-05-31
JO3342B1 (ar) 2019-03-13
HUE032306T2 (en) 2017-09-28
KR20150023880A (ko) 2015-03-05
JP6181172B2 (ja) 2017-08-16
TN2014000532A1 (en) 2016-03-30
SG11201408254UA (en) 2015-01-29
HRP20161745T1 (hr) 2017-02-24
WO2014001247A1 (en) 2014-01-03
PT2864291T (pt) 2017-01-06
CN104684896A (zh) 2015-06-03
DOP2014000295A (es) 2015-01-31
UY34881A (es) 2014-01-31
PH12014502869A1 (en) 2015-02-23
ES2609455T3 (es) 2017-04-20
MA37700B1 (fr) 2018-03-30
CA2877786C (en) 2020-08-25
MA20150269A1 (fr) 2015-08-31
TWI600646B (zh) 2017-10-01
EA201500039A1 (ru) 2015-06-30
EP2864291A1 (en) 2015-04-29
CR20140593A (es) 2015-02-16
TW201400460A (zh) 2014-01-01
EA028063B1 (ru) 2017-10-31
EP2864291B1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201690372A1 (ru) Азапиридоновые соединения и их применение
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
CL2015000543A1 (es) Derivados de alcanediil y alcanediil-c17, de ácido oleanólico compuestos intermediarios, composición parmacéutica y métodos asociados.
NZ723530A (en) Compounds as modulators of ror gamma
EA201591087A1 (ru) Новые производные бензимидазола в качестве антагонистов рецептора ep4
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
MY197440A (en) Heteroamatic compounds as btk inhibitors
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2014003443A1 (es) Compuestos derivados de n-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas; su metodo de produccion; compuestos intermediarios; producto medicinal que contiene al compuesto, util para el tratamiento y/o prevencion de enfermedades hiperproliferativas, las cuales son dependientes del receptor de androgenos.
ECSP13012893A (es) Ureas asimétricas y usos médicos de las mismas
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
PH12014501712B1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
EA201792234A1 (ru) Новые соединения пиридиния
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
FR3017386B1 (fr) Nouveau procede de preparation de 1,4,7-triazacyclononane (i) dissymetriques et intermediaires de synthese associes
UA112146C2 (uk) Спосіб отримання 4,1-бензоксатієпін-3-ону